Protein sumoylation in brain development, neuronal morphology and spinogenesis

NeuroMolecular Medicine

Volumn 15, Issue 4, 2013, Pages 677-691

  Gwizdek, Carole ^a   Cassé, Frédéric ^a   Martin, Stéphane ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Brain development; Posttranslational modification; Sumoylation; Synapse formation

Indexed keywords

BINDING PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; LEUCINE ZIPPER PROTEIN; METABOTROPIC RECEPTOR 8; MYOCYTE ENHANCER FACTOR 2; MYOCYTE SPECIFIC ENHANCER FACTOR 2A; NUCLEAR PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT 1; PROTEIN INHIBITOR OF ACTIVATED STAT 2; PROTEIN INHIBITOR OF ACTIVATED STAT 4; PROTEIN RANBP2; PROTEIN UBC9; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; SUMO 4 PROTEIN; SUMO PROTEIN; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PAX7; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; VISUAL PIGMENT;

ACETYLATION; BRAIN DEVELOPMENT; CASK GENE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; DENDRITIC SPINE; EMBRYO DEVELOPMENT; EYE DEVELOPMENT; GENE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MORPHOGENESIS; NONHUMAN; PAX GENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUMO1 GENE; SUMOYLATION; SYNAPTOGENESIS; UBIQUITINATION;

ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BRAIN; EMBRYONIC DEVELOPMENT; EUKARYOTIC CELLS; EYE PROTEINS; GUANYLATE KINASE; HUMANS; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEUROGENESIS; NEURONAL PLASTICITY; PAIRED BOX TRANSCRIPTION FACTORS; RECEPTORS, METABOTROPIC GLUTAMATE; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SPINAL CORD; SUMOYLATION; SYNAPTIC TRANSMISSION; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84888197260     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8252-z     Document Type: Review

References (121)

1. Abed, M.; Barry, K. C.; Kenyagin, D.; et al. (2011). Degringolade, a SUMO-targeted ubiquitin ligase, inhibits Hairy/Groucho-mediated repression. EMBO Journal, 30, 1289-1301.
2. Alkuraya, F. S.; Saadi, I.; Lund, J. J.; Turbe-Doan, A.; Morton, C. C.; Maas, R. L. (2006). SUMO1 haploinsufficiency leads to cleft lip and palate. Science, 313, 1751.
3. Aslanukov, A.; Bhowmick, R.; Guruju, M.; et al. (2006). RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism. PLoS Genetics, 2, e177.
4. Bernier-Villamor, V.; Sampson, D. A.; Matunis, M. J.; Lima, C. D. (2002). Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell, 108, 345-356.
5. Blackshaw, S.; Harpavat, S.; Trimarchi, J.; et al. (2004). Genomic analysis of mouse retinal development. PLoS Biology, 2, E247.
6. Bohren, K. M.; Nadkarni, V.; Song, J. H.; Gabbay, K. H.; Owerbach, D. (2004). A M55 V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. Journal of Biological Chemistry, 279, 27233-27238.
7. Bramham, C. R.; Alme, M. N.; Bittins, M.; et al. (2010). The Arc of synaptic memory. Experimental Brain Research, 200, 125-140.
8. Braschi, E.; Zunino, R.; McBride, H. M. (2009). MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. EMBO Reports, 10, 748-754.
9. Chao, H. W.; Hong, C. J.; Huang, T. N.; Lin, Y. L.; Hsueh, Y. P. (2008). SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis. Journal of Cell Biology, 182, 141-155.
10. Cheng, J.; Kang, X.; Zhang, S.; Yeh, E. T. (2007). SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 131, 584-595.
11. Chiu, S. Y.; Asai, N.; Costantini, F.; Hsu, W. (2008). SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biology, 6, e310.
12. Cho, K. I.; Yi, H.; Yeh, A.; et al. (2009). Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons. Cell Death and Differentiation, 16, 287-297.
13. Craig, T. J.; Jaafari, N.; Petrovic, M. M.; Rubin, P. P.; Mellor, J. R.; Henley, J. M. (2012). Homeostatic synaptic scaling is regulated by protein SUMOylation. Journal of Biological Chemistry, 287, 22781-22788.
14. Dai, X. Q.; Plummer, G.; Casimir, M.; et al. (2011). SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. Diabetes, 60, 838-847.
15. Dawlaty, M. M.; Malureanu, L.; Jeganathan, K. B.; et al. (2008). Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell, 133, 103-115.
16. de Cristofaro, T.; Mascia, A.; Pappalardo, A.; D'Andrea, B.; Nitsch, L.; Zannini, M. (2009). Pax8 protein stability is controlled by sumoylation. Journal of Molecular Endocrinology, 42, 35-46.
17. Demarque, M. D.; Nacerddine, K.; Neyret-Kahn, H.; et al. (2011). Sumoylation by Ubc9 regulates the stem cell compartment and structure and function of the intestinal epithelium in mice. Gastroenterology, 140, 286-296.
18. Denuc, A.; Marfany, G. (2010). SUMO and ubiquitin paths converge. Biochemical Society Transactions, 38, 34-39.
19. Dutting, E.; Schroder-Kress, N.; Sticht, H.; Enz, R. (2011). SUMO E3 ligases are expressed in the retina and regulate SUMOylation of the metabotropic glutamate receptor 8b. The Biochemical Journal, 435, 365-371.
20. Enz, R. (2012). Structure of metabotropic glutamate receptor C-terminal domains in contact with interacting proteins. Frontiers in Molecular Neuroscience, 5, 52.
21. Evdokimov, E.; Sharma, P.; Lockett, S. J.; Lualdi, M.; Kuehn, M. R. (2008). Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. Journal of Cell Science, 121, 4106-4113.
22. Fei, E.; Jia, N.; Yan, M.; et al. (2006). SUMO-1 modification increases human SOD1 stability and aggregation. Biochemical and Biophysical Research Communications, 347, 406-412.
23. Feligioni, M.; Nishimune, A.; Henley, J. M. (2009). Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals. European Journal of Neuroscience, 29, 1348-1356.
24. Flavell, S. W.; Greenberg, M. E. (2008). Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annual Review of Neuroscience, 31, 563-590.
25. Flavell, S. W.; Kim, T. K.; Gray, J. M.; et al. (2008). Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron, 60, 1022-1038.
26. Gao, C.; Ho, C. C.; Reineke, E.; et al. (2008). Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Molecular and Cellular Biology, 28, 5658-5667.
27. Gareau, J. R.; Lima, C. D. (2010). The SUMO pathway: Emerging mechanisms that shape specificity, conjugation and recognition. Nature Reviews Molecular Cell Biology, 11, 861-871.
28. Gareau, J. R.; Reverter, D.; Lima, C. D. (2012). Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2. Journal of Biological Chemistry, 287, 4740-4751.
29. Geiss-Friedlander, R.; Melchior, F. (2007). Concepts in sumoylation: A decade on. Nature Reviews Molecular Cell Biology, 8, 947-956.
30. Geoffroy, M. C.; Jaffray, E. G.; Walker, K. J.; Hay, R. T. (2010). Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Molecular Biology of the Cell, 21, 4227-4239.
31. Gong, L.; Li, B.; Millas, S.; Yeh, E. T. (1999). Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Letters, 448, 185-189.
32. Gong, L.; Millas, S.; Maul, G. G.; Yeh, E. T. (2000). Differential regulation of sentrinized proteins by a novel sentrin-specific protease. Journal of Biological Chemistry, 275, 3355-3359.
33. Gregoire, S.; Tremblay, A. M.; Xiao, L.; et al. (2006). Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. Journal of Biological Chemistry, 281, 4423-4433.
34. Gregoire, S.; Yang, X. J. (2005). Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Molecular and Cellular Biology, 25, 2273-2287.
35. Guo, D.; Li, M.; Zhang, Y.; et al. (2004). A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nature Genetics, 36, 837-841.
36. Hackett, A.; Tarpey, P. S.; Licata, A.; et al. (2010). CASK mutations are frequent in males and cause X-linked nystagmus and variable XLMR phenotypes. European Journal of Human Genetics, 18, 544-552.
37. Haider, N. B.; Jacobson, S. G.; Cideciyan, A. V.; et al. (2000). Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nature Genetics, 24, 127-131.
38. Hammer, E.; Heilbronn, R.; Weger, S. (2007). The E3 ligase Topors induces the accumulation of polysumoylated forms of DNA topoisomerase I in vitro and in vivo. FEBS Letters, 581, 5418-5424.
39. Hay, R. T. (2005). SUMO: A history of modification. Molecular Cell, 18, 1-12.
40. Hayashi, T.; Seki, M.; Maeda, D.; et al. (2002). Ubc9 is essential for viability of higher eukaryotic cells. Experimental Cell Research, 280, 212-221.
41. Hickey, C. M.; Wilson, N. R.; Hochstrasser, M. (2012). Function and regulation of SUMO proteases. Nature Reviews Molecular Cell Biology, 13, 755-766.
42. Hoeller, D.; Hecker, C. M.; Wagner, S.; Rogov, V.; Dotsch, V.; Dikic, I. (2007). E3-independent monoubiquitination of ubiquitin-binding proteins. Molecular Cell, 26, 891-898.
43. Huang, Q.; Figueiredo-Pereira, M. E. (2010). Ubiquitin/proteasome pathway impairment in neurodegeneration: Therapeutic implications. Apoptosis, 15, 1292-1311.
44. Hunter, T.; Sun, H. (2009). Crosstalk between the SUMO and ubiquitin pathways. Ernst Schering Foundation Symposium Proceedings, Vol. 2008/1, pp. 1-16.
45. Jaafari, N.; Konopacki, F. A.; Owen, T. F.; et al. (2013). SUMOylation is required for glycine-induced increases in AMPA receptor surface expression (ChemLTP) in hippocampal neurons. PLoS One, 8, e52345.
46. Janer, A.; Werner, A.; Takahashi-Fujigasaki, J.; et al. (2010). SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. Human Molecular Genetics, 19, 181-195.
47. Johnson, E. S. (2004). Protein modification by SUMO. Annual Review of Biochemistry, 73, 355-382.
48. Kagey, M. H.; Melhuish, T. A.; Wotton, D. (2003). The polycomb protein Pc2 is a SUMO E3. Cell, 113, 127-137.
49. Kahyo, T.; Nishida, T.; Yasuda, H. (2001). Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Molecular Cell, 8, 713-718.
50. Kang, J.; Gocke, C. B.; Yu, H. (2006). Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity. BMC Biochemistry, 7, 5.
51. Kang, X.; Qi, Y.; Zuo, Y.; et al. (2010). SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Molecular Cell, 38, 191-201.
52. Kantamneni, S.; Wilkinson, K. A.; Jaafari, N.; et al. (2011). Activity-dependent SUMOylation of the brain-specific scaffolding protein GISP. Biochemical and Biophysical Research Communications, 409, 657-662.
53. Kerscher, O. (2007). SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Reports, 8, 550-555.
54. Kim, E. Y.; Chen, L.; Ma, Y.; et al. (2012). Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction. Journal of Molecular and Cellular Cardiology, 52, 638-649.
55. Kolli, N.; Mikolajczyk, J.; Drag, M.; et al. (2010). Distribution and paralogue specificity of mammalian deSUMOylating enzymes. The Biochemical Journal, 430, 335-344.
56. Kotaja, N.; Karvonen, U.; Janne, O. A.; Palvimo, J. J. (2002). PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Molecular and Cellular Biology, 22, 5222-5234.
57. Krumova, P.; Meulmeester, E.; Garrido, M.; et al. (2011). Sumoylation inhibits {alpha}-synuclein aggregation and toxicity. Journal of Cell Biology, 194, 49-60.
58. Krumova, P.; Weishaupt, J. H. (2013). Sumoylation in neurodegenerative diseases. Cellular and Molecular Life Sciences, 70, 2123-2138.
59. Lee, Y. J.; Mou, Y.; Maric, D.; Klimanis, D.; Auh, S.; Hallenbeck, J. M. (2011). Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One, 6, e25852.
60. Li, Y.; Wang, H.; Wang, S.; Quon, D.; Liu, Y. W.; Cordell, B. (2003). Positive and negative regulation of APP amyloidogenesis by sumoylation. Proceedings of the National Academy of Sciences of the USA, 100, 259-264.
61. Liu, B.; Mink, S.; Wong, K. A.; et al. (2004). PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nature Immunology, 5, 891-898.
62. Loriol, C.; Khayachi, A.; Poupon, G.; Gwizdek, C.; Martin, S. (2013). Activity-dependent regulation of the sumoylation machinery in rat hippocampal neurons. Biology of the Cell, 105, 30-45.
63. Loriol, C.; Parisot, J.; Poupon, G.; Gwizdek, C.; Martin, S. (2012). Developmental regulation and spatiotemporal redistribution of the sumoylation machinery in the rat central nervous system. PLoS One, 7, e33757.
64. Lu, H.; Liu, B.; You, S.; et al. (2012). SENP2 regulates MEF2A de-SUMOylation in an activity dependent manner. Molecular Biology Reports, 40, 2485-2490.
65. Luan, Z.; Liu, Y.; Stuhlmiller, T. J.; Marquez, J.; Garcia-Castro, M. I. (2013). SUMOylation of Pax7 is essential for neural crest and muscle development. Cellular and Molecular Life Sciences, 70, 1793-1806.
66. Marblestone, J. G.; Edavettal, S. C.; Lim, Y.; Lim, P.; Zuo, X.; Butt, T. R. (2006). Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO. Protein Science, 15, 182-189.
67. Marshall, H.; Bhaumik, M.; Aviv, H.; et al. (2010). Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice. BMC Molecular Biology, 11, 31.
68. Martin, S. (2009). Extranuclear functions of protein sumoylation in the central nervous system. Medicine Science (Paris), 25, 693-698.
69. Martin, S.; Nishimune, A.; Mellor, J. R.; Henley, J. M. (2007a). SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature, 447, 321-325.
70. Martin, S.; Wilkinson, K. A.; Nishimune, A.; Henley, J. M. (2007b). Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nature Reviews Neuroscience, 8, 948-959.
71. Mears, A. J.; Kondo, M.; Swain, P. K.; et al. (2001). Nrl is required for rod photoreceptor development. Nature Genetics, 29, 447-452.
72. Mikkonen, L.; Hirvonen, J.; Janne, O. A. (2013). SUMO-1 regulates body weight and adipogenesis via PPARgamma in male and female mice. Endocrinology, 154, 698-708.
73. Morita, Y.; Kanei-Ishii, C.; Nomura, T.; Ishii, S. (2005). TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Molecular Biology of the Cell, 16, 5433-5444.
74. Mukhopadhyay, D.; Dasso, M. (2007). Modification in reverse: The SUMO proteases. Trends in Biochemical Sciences, 32, 286-295.
75. Nacerddine, K.; Lehembre, F.; Bhaumik, M.; et al. (2005). The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Developmental Cell, 9, 769-779.
76. Namanja, A. T.; Li, Y. J.; Su, Y.; et al. (2012). Insights into high affinity small ubiquitin-like modifier (SUMO) recognition by SUMO-interacting motifs (SIMs) revealed by a combination of NMR and peptide array analysis. Journal of Biological Chemistry, 287, 3231-3240.
77. Nishida, T.; Yasuda, H. (2002). PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. Journal of Biological Chemistry, 277, 41311-41317.
78. Onishi, A.; Peng, G. H.; Hsu, C.; Alexis, U.; Chen, S.; Blackshaw, S. (2009). Pias3-dependent SUMOylation directs rod photoreceptor development. Neuron, 61, 234-246.
79. Pichler, A.; Gast, A.; Seeler, J. S.; Dejean, A.; Melchior, F. (2002). The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell, 108, 109-120.
80. Pichler, A.; Knipscheer, P.; Saitoh, H.; Sixma, T. K.; Melchior, F. (2004). The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type. Nature Structural & Molecular Biology, 11, 984-991.
81. Potts, P. R.; Yu, H. (2005). Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Molecular and Cellular Biology, 25, 7021-7032.
82. Potts, P. R.; Yu, H. (2007). The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nature Structural & Molecular Biology, 14, 581-590.
83. Rajendra, R.; Malegaonkar, D.; Pungaliya, P.; et al. (2004). Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. Journal of Biological Chemistry, 279, 36440-36444.
84. Reverter, D.; Lima, C. D. (2005). Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature, 435, 687-692.
85. Riley, B. E.; Zoghbi, H. Y.; Orr, H. T. (2005). SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. Journal of Biological Chemistry, 280, 21942-21948.
86. Riquelme, C.; Barthel, K. K.; Liu, X. (2006). SUMO-1 modification of MEF2A regulates its transcriptional activity. Journal of Cellular and Molecular Medicine, 10, 132-144.
87. Rodriguez, M. S.; Dargemont, C.; Hay, R. T. (2001). SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. Journal of Biological Chemistry, 276, 12654-12659.
88. Roger, J. E.; Nellissery, J.; Kim, D. S.; Swaroop, A. (2010). Sumoylation of bZIP Transcription Factor NRL Modulates Target Gene Expression during Photoreceptor Differentiation. Journal of Biological Chemistry, 285, 25637-25644.
89. Rubio, M. D.; Wood, K.; Haroutunian, V.; Meador-Woodruff, J. H. (2013). Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia. Neuropsychopharmacology,. doi: 10.1038/npp.2013.84.
90. Rytinki, M. M.; Kaikkonen, S.; Pehkonen, P.; Jaaskelainen, T.; Palvimo, J. J. (2009). PIAS proteins: Pleiotropic interactors associated with SUMO. Cellular and Molecular Life Sciences, 66, 3029-3041.
91. Sachdev, S.; Bruhn, L.; Sieber, H.; Pichler, A.; Melchior, F.; Grosschedl, R. (2001). PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes & Development, 15, 3088-3103.
92. Sampson, D. A.; Wang, M.; Matunis, M. J. (2001). The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. Journal of Biological Chemistry, 276, 21664-21669.
93. Santti, H.; Mikkonen, L.; Anand, A.; et al. (2005). Disruption of the murine PIASx gene results in reduced testis weight. Journal of Molecular Endocrinology, 34, 645-654.
94. Saracco, S. A.; Miller, M. J.; Kurepa, J.; Vierstra, R. D. (2007). Genetic analysis of SUMOylation in Arabidopsis: Conjugation of SUMO1 and SUMO2 to nuclear proteins is essential. Plant Physiology, 145, 119-134.
95. Schmidt, D.; Muller, S. (2002). Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proceedings of the National Academy of Sciences of the USA, 99, 2872-2877.
96. Shalizi, A.; Bilimoria, P. M.; Stegmuller, J.; et al. (2007). PIASx is a MEF2 SUMO E3 ligase that promotes postsynaptic dendritic morphogenesis. Journal of Neuroscience, 27, 10037-10046.
97. Shalizi, A.; Gaudilliere, B.; Yuan, Z.; et al. (2006). A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science, 311, 1012-1017.
98. Sharma, P.; Yamada, S.; Lualdi, M.; Dasso, M.; Kuehn, M. R. (2013). Senp1 Is Essential for Desumoylating Sumo1-Modified Proteins but Dispensable for Sumo2 and Sumo3 Deconjugation in the Mouse Embryo. Cell Reports, 3, 1640-1650.
99. Shin, E. J.; Shin, H. M.; Nam, E.; et al. (2012). DeSUMOylating isopeptidase: A second class of SUMO protease. EMBO Reports, 13, 339-346.
100. Shinbo, Y.; Niki, T.; Taira, T.; et al. (2006). Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death and Differentiation, 13, 96-108.
101. Steffan, J. S.; Agrawal, N.; Pallos, J.; et al. (2004). SUMO modification of Huntingtin and Huntington's disease pathology. Science, 304, 100-104.
102. Subramaniam, S.; Mealer, R. G.; Sixt, K. M.; Barrow, R. K.; Usiello, A.; Snyder, S. H. (2010). Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9. Journal of Biological Chemistry, 285, 20428-20432.
103. Subramaniam, S.; Sixt, K. M.; Barrow, R.; Snyder, S. H. (2009). Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science, 324, 1327-1330.
104. Tang, Z.; El Far, O.; Betz, H.; Scheschonka, A. (2005). Pias1 interaction and sumoylation of metabotropic glutamate receptor 8. Journal of Biological Chemistry, 280, 38153-38159.
105. Tatham, M. H.; Geoffroy, M. C.; Shen, L.; et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nature Cell Biology, 10, 538-546.
106. Thompson, J. A.; Ziman, M. (2011). Pax genes during neural development and their potential role in neuroregeneration. Progress in Neurobiology, 95, 334-351.
107. Ulrich, H. D. (2005). Mutual interactions between the SUMO and ubiquitin systems: A plea of no contest. Trends in Cell Biology, 15, 525-532.
108. Van Nguyen, T.; Angkasekwinai, P.; Dou, H.; et al. (2012). SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Molecular Cell, 45, 210-221.
109. Venteclef, N.; Jakobsson, T.; Ehrlund, A.; et al. (2010). GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes & Development, 24, 381-395.
110. Wang, J.; Chen, L.; Wen, S.; et al. (2011). Defective sumoylation pathway directs congenital heart disease. Birth Defects Research. Part A, Clinical and Molecular Teratology, 91, 468-476.
111. Watanabe, M.; Takahashi, K.; Tomizawa, K.; Mizusawa, H.; Takahashi, H. (2008). Developmental regulation of Ubc9 in the rat nervous system. Acta Biochimica Polonica, 55, 681-686.
112. Weger, S.; Hammer, E.; Heilbronn, R. (2005). Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Letters, 579, 5007-5012.
113. Whitford, K. L.; Dijkhuizen, P.; Polleux, F.; Ghosh, A. (2002). Molecular control of cortical dendrite development. Annual Review of Neuroscience, 25, 127-149.
114. Wilkinson, K. A.; Nakamura, Y.; Henley, J. M. (2010). Targets and consequences of protein SUMOylation in neurons. Brain Research Reviews, 64, 195-212.
115. Wilkinson, K. A.; Nishimune, A.; Henley, J. M. (2008). Analysis of SUMO-1 modification of neuronal proteins containing consensus SUMOylation motifs. Neuroscience Letters, 436, 239-244.
116. Wong, K. A.; Kim, R.; Christofk, H.; Gao, J.; Lawson, G.; Wu, H. (2004). Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Molecular and Cellular Biology, 24, 5577-5586.
117. Xu, Y.; Zuo, Y.; Zhang, H.; et al. (2010). Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. Journal of Biological Chemistry, 285, 36682-36688.
118. Yamaguchi, T.; Sharma, P.; Athanasiou, M.; Kumar, A.; Yamada, S.; Kuehn, M. R. (2005). Mutation of SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Molecular and Cellular Biology, 25, 5171-5182.
119. Yan, Q.; Gong, L.; Deng, M.; et al. (2010). Sumoylation activates the transcriptional activity of Pax-6, an important transcription factor for eye and brain development. Proceedings of the National Academy of Sciences of the USA, 107, 21034-21039.
120. Yu, L.; Ji, W.; Zhang, H.; et al. (2010). SENP1-mediated GATA1 deSUMOylation is critical for definitive erythropoiesis. Journal of Experimental Medicine, 207, 1183-1195.
121. Zhang, F. P.; Mikkonen, L.; Toppari, J.; Palvimo, J. J.; Thesleff, I.; Janne, O. A. (2008). Sumo-1 function is dispensable in normal mouse development. Molecular and Cellular Biology, 28, 5381-5390.